FAIR ACT

Bill Number

H.R. 7953

Origin Chamber

House

Congress

119th Congress, Session 2

Policy Area

Health

Status

Introduced

Latest Action

2026-03-17: Referred to the House Committee on Energy and Commerce.

Last Updated

2026-06-11T23:26:38Z

AI-Generated Summary

Purpose

The FAIR ACT (Fast-tracking Approval for Innovative Rare disease therapies Act) aims to speed up U.S. patient access to innovative drugs and clinical trials for life-threatening diseases by creating a reciprocal approval process with select trusted foreign regulators, reducing delays caused by the FDA's standard review timeline.

Key Provisions

• Reciprocal Marketing Approval (New Section 524C of FD&C Act):
• Applies to "covered products" (drugs or biological products) for immediately life-threatening diseases or conditions (e.g., diseases where death is likely without treatment).
• FDA must grant approval within 30 days if the product is lawfully marketed in a foreign country by a trusted international regulatory authority (e.g., European Medicines Agency, UK MHRA, Health Canada, or others designated by HHS), with no prior safety-related withdrawals.
• Requires sponsor submission of foreign approval documents (English translation if needed); FDA finalizes labeling and any post-market studies (e.g., ongoing safety monitoring) during this period.
• Treats these approvals like standard FDA approvals for labeling, post-market rules, and fees.
• FDA can withdraw approval anytime based on new evidence of serious risks or if the foreign approval is pulled; may include phase-out plans for patients.

• Reciprocal Clinical Trial Allowance (New Section 569B-1):
• Allows manufacturers to run U.S. clinical trials (under IND rules) if already authorized by a trusted foreign regulator.
• FDA must approve or deny within 30 days, treating it like a standard IND application; can request protocol changes but must decide on time.
• Same rules apply as regular trials.

• Reporting Requirement: FDA must report to Congress after 5 years on program effectiveness, approvals/denials, safety impacts, and recommendations.

Significant Changes to Existing Law

• Introduces a 30-day fast-track for marketing approvals and clinical trials, bypassing full FDA review for eligible foreign-approved products—contrasting with typical FDA timelines of months or years.
• Relies on foreign regulators' data instead of requiring full U.S.-specific trials or reviews upfront.
• Expands FDA fee authority and post-market oversight to these pathways.

Potential Impacts

• Patients: Faster access to cutting-edge treatments for life-threatening conditions, potentially saving lives but with reliance on foreign safety data.
• Government Agencies (FDA/HHS): Streamlined processes for specific cases, increased workload for reviews/withdrawals, and mandatory reporting.
• Drug Developers: Quicker U.S. market entry and more domestic trials, countering shifts abroad (e.g., to China).
• International Relations: Builds cooperation with trusted regulators (Europe, UK, Canada); highlights U.S. concerns over competitors like China.

Main Stakeholders

• Patients with life-threatening diseases.
• Drug sponsors/manufacturers seeking faster approvals.
• FDA and HHS (implementation, oversight, designations).
• Trusted foreign regulators (EMA, MHRA, Health Canada).
• Congress (oversight via committees like Energy and Commerce).

Notable Legal, Constitutional, or Political Implications

• Legal: Shifts some safety validation to foreign authorities, with FDA safeguards (e.g., withdrawals); treats reciprocal approvals as equivalent to full FDA nods, potentially facing court challenges on safety standards.
• Constitutional: None directly implicated; aligns with Congress's commerce clause authority over drugs.
• Political: Bipartisan (introduced by Reps. Sessions and Peters); emphasizes U.S. biomedical leadership amid global competition, with built-in 5-year review for future adjustments.

This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.

Sponsor

Rep. Sessions, Pete [R-TX-17]

Cosponsors (2)

Rep. Peters, Scott H. [D-CA-50], Rep. Moulton, Seth [D-MA-6]

Recent Actions

• 2026-03-17: Referred to the House Committee on Energy and Commerce.
• 2026-03-17: Introduced in House
• 2026-03-17: Introduced in House

Bill Versions

• Fast-tracking Approval for Innovative Rare disease therapies Act — issued 2026-03-17 — PDF (11 pages)